Vertaile menetelmiä
Tarkastele valitsemiasi menetelmiä rinnakkain; eroavat rivit korostetaan.
| Addenbrooke's kognitiivinen arviointi× | Alzheimerin taudin arviointiasteikko – kognitiivinen osa-alue× | |
|---|---|---|
| Tieteenala | Neuropsykologia | Neuropsykologia |
| Menetelmäperhe | Process / pipeline | Process / pipeline |
| Syntyvuosi≠ | 2000 | 1984 |
| Kehittäjä≠ | Padasalai Mathuranath | William Rosen |
| Tyyppi≠ | Clinician-administered comprehensive cognitive examination | Clinician-administered cognitive scale for Alzheimer's disease |
| Alkuperäislähde≠ | Mathuranath, P. S., Nestor, P. J., Berrios, G. E., Rakowicz, W., & Hodges, J. R. (2000). A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology, 55(11), 1613-1620. DOI ↗ | Rosen, W. G., Mohs, R. C., & Davis, K. L. (1984). A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141(11), 1356-1364. DOI ↗ |
| Rinnakkaisnimet≠ | ACE, ACE-R, ACE-III, Addenbrooke Cognitive Examination | ADAS-Cog, ADAS-Cog14, ADAS-Cog13 |
| Liittyvät | 5 | 5 |
| Tiivistelmä≠ | The Addenbrooke's Cognitive Examination (ACE) is a brief yet comprehensive clinician-administered cognitive battery designed to assess multiple cognitive domains and differentiate between types of dementia. Originally developed by Mathuranath and colleagues at Cambridge University in 2000, the ACE was created to address limitations of single-domain screening tools. The revised version (ACE-R, 2006) and further refined version (ACE-III, 2013) provide updated norms and improved sensitivity. The ACE-R and ACE-III are particularly valuable for distinguishing Alzheimer's disease from frontotemporal dementia. | The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) is a clinician-administered cognitive assessment instrument designed specifically to measure cognitive decline in Alzheimer's disease. Developed by Rosen, Mohs, and Davis in 1984 and published in the American Journal of Psychiatry, the ADAS-Cog has become the gold standard outcome measure in pharmaceutical trials of antidementia drugs. It is sensitive to disease progression and capable of detecting cognitive change over periods as brief as 6–12 months. |
| ScholarGateAineisto ↗ |
|
|